Trading in Isofol’s shares commences today on Nasdaq Stockholm
GOTHENBURG, Sweden, October 21, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that […]
English
Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm
GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm
GOTHENBURG, Sweden, October 15, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Company presentation at LSX Nordic Congress 2021
From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with Nordic life science executives focused
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held
Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol completes recruitment of Japanese patients in the global phase III AGENT study
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million
GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that